From GlobeNewswire: 2025-06-02 01:00:00

Sanofi has agreed to acquire Blueprint Medicines, a biopharmaceutical company specializing in rare immunological diseases. The acquisition includes Ayvakit/Ayvakyt, the only approved medicine for advanced systemic mastocytosis, and promises a strong pipeline in immunology. The deal is valued at approximately $9.1 billion in cash, with potential milestone payments. Sanofi aims to enhance its immunology portfolio and become a leading immunology company. Blueprint’s CEO, Kate Haviland, expressed pride in the medical innovations created by the company. The acquisition is expected to bring life-changing medicines to more patients worldwide. The transaction is expected to close in the third quarter of 2025.



Read more at GlobeNewswire: Sanofi to acquire Blueprint Medicines,